CoChat

Genetics of Parkinson's disease: LRRK2 on the rise

Open access
Brice, Alexis · 2005 · Brain
Cited by 90

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Our view of the pathogenic mechanisms of Parkinson's disease has greatly changed over the past decade with the identification of several genes implicated in Mendelian forms of this disorder (Corti et al., 2005; Gasser et al., 2005). Parkin, DJ-1 and PINK1 are responsible for autosomal recessive forms, usually with early onset, that are not associated with Lewy bodies. α-Synuclein was considered to be the major gene responsible for autosomal dominant forms until late 2004, when the LRRK2 gene was identified (Paisan-Ruiz et al., 2004; Zimprich et al., 2004a). Despite their rarity, the discovery of α-synuclein mutations or multiplications led to the demonstration that α-synuclein is the major component of Lewy bodies, and clearly illustrated the gene dosage effect resulting from gene multiplications; duplications of the α-synuclein gene are responsible for a late-onset typical Parkinson's disease (Chartier-Harlin et al., 2004; Ibanez et al., 2004), whereas triplications result in an early-onset and rapidly progressive dementia with Lewy bodies (Singleton et al., 2003), indicating the importance of the number of functional copies of this gene. It now turns out that LRRK2 is much more frequent and also has interesting features. The LRRK2 gene encodes a putative protein kinase named dardarin from dardara, the Basque term for tremor. From previous reports of LRRK2 families, it is known that the phenotype is mostly that of typical late-onset dopa-responsive Parkinson's disease, but with some intrafamilial variability (Funayama et al., 2002; Nicholl et al., 2002; Zimprich et al., 2004b). The most striking variability concerns the neuropathological features. Although the dopaminergic neurons of the substantia nigra degenerate in all patients in association with gliosis, other pathological markers vary, even within the same family (Wszolek et al., 2004). Several patients have the pathological hallmark of Parkinson's disease: α-synuclein-positive Lewy bodies in the brainstem which may extend to the cerebral cortex as in diffuse Lewy body disease. Others have tau pathology as in progressive supranuclar palsy, and still others may have neither α-synuclein nor tau deposits, but nigral degeneration without any distinctive histopathological features. Finally β-amyloid deposits or anterior horn cell loss with axonal spheroids have been found in several cases. These observations show that the same disease can have multiple pathological expressions, challenging the accepted neuropathological criteria for Parkinson's disease. Another recent finding is the frequency of the G2019S LRRK2 mutation, which accounts for 3–41% of familial Parkinson's disease (Di Fonzo et al., 2005; Kachergus et al., 2005; Lesage et al., 2005a; Mata et al., 2005; Nichols et al., 2005; Zabetian et al., 2005). A north–south gradient of distribution is suspected because the frequency of this mutation is low in Northern Europe, increasing in Southern Europe and exploding in North Africa. The G2019S mutation is also found, although at a lower rate (1–2%), in apparently sporadic cases from Europe (Bras et al., 2005; Farrer et al., 2005; Gilks et al., 2005; Hernandez et al., 2005; Zabetian et al., 2005) but not from Asia (Tan et al., 2005). Interestingly, this mutation is associated with the same haplotype in different populations, indicating the existence of a common founder which probably lived in the 13th century (Kachergus et al., 2005; Lesage et al., 2005b). In this issue of Brain, three papers extend our knowledge of several features of LRRK2 gene mutations (Adams et al., 2005; Berg et al., 2005; Khan et al., 2005). The first provides information on brain metabolism with TEP studies in affected and unaffected members of two families with LRRK2 mutations (Adams et al., 2005). The other two report clinical and genetic findings in new LRRK2 positive families (Berg et al., 2005; Khan et al., 2005). In their series of 51 families with Parkinson's disease, mostly from Germany, Berg et al. (2005) identified 7 families with LRRK2 mutations, 4 of which had novel missense mutations, but the common G2019S mutation was not found. In contrast, Khan et al. (2005) found 6 out of 118 families with LRRK2 mutations: 2 with novel missense mutations and 3 with the G2019S mutation. There are now 16 identified LRRK2 mutations. Interestingly, all but one of these mutations are missense and all but 2 are located in functional domains of the protein (Fig. 1). In accordance with previous series of families mostly from Europe, LRRK2 accounted for 5–>10% of familial cases (Zimprich et al., 2004a; Mata et al., 2005). Age at onset varied within families, as already observed for the G2019S mutation, where it ranges from 28 to 86 years. Furthermore, penetrance is age-dependent and might also be reduced. In a family with the Q930R mutation, an obligate carrier died at the age of 90 years with no sign of parkinsonism (Berg et al., 2005), similar to a healthy octogenarian recently describ

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awh676

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 90

Metadata

Authors
Brice, A.
Venue
Brain
Published
2005-12-01
Volume
128
Issue
12
Pages
2760-2762
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2103306563
Cited by
90
References
3
FWCI
6.05
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetics of Parkinson's disease: LRRK2 on the rise. https://app.cochat.ai/papers/10.1093/brain/awh676
The paper
Brice, A. (2005). Genetics of Parkinson's disease: LRRK2 on the rise. Brain. https://doi.org/10.1093/brain/awh676

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.